Dysport™ represents the first new botulinum toxin type A treatment option in eight years to reach the U.S. market place. Dysport™ (abobotulinumtoxinA) inhibits release of the neurotransmitter acetylcholine from peripheral cholinergic nerve endings, which reduces muscular spasm. The active ingredient in Dysport™ is a botulinum toxin type A, which acts at the level of the neuromuscular junction in the targeted muscle. Dysport™ inhibits release of the neurotransmitter acetylcholine from peripheral cholinergic nerve endings, which reduces muscular spasm. It is the first competitor for BOTOX® Cosmetic and Dr. Egan was involved in the scientific studies that brought it to the U.S. market. The experience from the studies done by Dr. Egan has shown that Dysport™ can produce longer lasting results of up to 6-8 months.
Lunchtime Browlift
Dysport™ can also be used to create a subtle lifting of the brow which can delay or eliminate the need for browlift surgery. Call for a consultation appointment today to learn more about Dysport™